Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland

BACKGROUND: Tumor necrosis factor (TNF) inhibitors have improved treatment of ulcerative colitis (UC), but loss of response remains a frequent problem. The anti-TNF agent, golimumab, was approved in Switzerland for the treatment of UC in 2014. This study aims to summarize the experience of golimumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrig, Kathrin, Krupka, Niklas, Jordi, Sebastian Bruno Ulrich, Rossel, Jean-Benoît, Biedermann, Luc, Greuter, Thomas, Schreiner, Philipp, Vavricka, Stephan R., Juillerat, Pascal, Burri, Emanuel, Zimmermann, Dorothee, Maillard, Michel H., Sulz, Michael Christian, Brand, Stephan, Rogler, Gerhard, Misselwitz, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832575/
https://www.ncbi.nlm.nih.gov/pubmed/35154389
http://dx.doi.org/10.1177/17562848221074188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832575/
https://www.ncbi.nlm.nih.gov/pubmed/35154389
http://dx.doi.org/10.1177/17562848221074188

Ejemplares similares